EFB Dengue Literature Review

Extrafollicular Response

55 min read

Extrafollicular Response

Overview

The extrafollicular (EF) B cell response refers to antigen-driven B cell activation and differentiation that occurs outside of germinal centres — in the T cell zones and red pulp of the spleen, interfollicular areas of lymph nodes, and other extrafollicular anatomical niches. EF responses can produce short-lived plasmablasts, and in some contexts generate memory B cells with somatic hypermutation, without the full complement of GC-associated signals (particularly CD27 acquisition and high-rate SHM).

The EF response is increasingly recognised as a major branch of humoral immunity in acute viral infections, autoimmune diseases, and conditions of immune dysregulation. In this wiki it is the generating pathway under the atypical (DN) B-cell + plasmablast spine — the GC-independent route proposed to produce the atypical/DN cells and plasmablasts that are the wiki’s focus, specifically as it pertains to dengue infection, a context where this differentiation has been proposed but not yet comprehensively characterised.

Key Points from Literature

  • EF origin hypothesis for DN B cells: Wei et al. propose that IgD⁻CD27⁻ (double-negative) memory B cells in SLE develop via extrafollicular pathways, based on: (1) CD27 being normally acquired during GC reactions via CD40–CD154 interactions; (2) DN cells showing lower SHM rates (~3%) than CD27⁺ GC-derived memory cells (~5%); (3) murine evidence that SHM can occur in EF reactions (see William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice) (see Wei2007 - DN Memory B Cells in SLE, cross-sectional SLE cohort).

  • DC-mediated EF B cell activation: Qi et al. (2006, Science) showed that antigen-bearing dendritic cells can activate lymph node B cells in extrafollicular zones — cited in Wei2007 - DN Memory B Cells in SLE as mechanistic support for EF memory B cell generation.

  • CD40-independent class switching: Litinskiy et al. (2002, Nat Immunol) demonstrated that DCs can induce IgG/IgA class switching via BLyS and APRIL without CD40 signals — providing an EF route to isotype-switched antibodies (cited in Wei2007 - DN Memory B Cells in SLE).

  • EF responses in autoimmunity: The expansion of DN B cells in SLE, correlating with nephritis and autoreactive antibodies, suggests that pathological EF responses can generate autoreactive memory and potentially contribute to disease. This is in contrast to GC reactions, which in SLE appear dysregulated rather than absent (see Wei2007 - DN Memory B Cells in SLE).

  • DN expansion is driven by ongoing B cell dysregulation, not fixed programming: After rituximab-mediated B cell depletion and immune reconstitution, DN expansion resolved in effective depletors (P=0.05). This demonstrates that DN accumulation requires continuous input — likely from dysregulated naive/memory B cell precursors — rather than irreversible epigenetic programming of individual clones. In patients with incomplete depletion, resolution did not occur (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE, phase I/II trial n=17).

  • Correlation between EF B cell expansion and disease severity: DN expansion correlates with VH4.34 autoreactive antibody titers (R²=0.8, P<0.05), stronger than the correlation for naive lymphopenia alone. This quantitative link supports the idea that EF-derived DN B cells are not bystander expansions but participate in the autoimmune process (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE).

  • EF plasmablast dynamics: Circulating plasmablasts in SLE are predominantly short-lived (CD20⁻) cells replenished by CD20⁺ B cell precursors; their rapid decline after rituximab suggests they are products of ongoing EF differentiation rather than accumulated long-lived cells (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE; see also Plasmablast).

  • Direct naive → EF → ASC pathway demonstrated in human SLE: A distinct subset of activated naive (acN) B cells (CD19^hi, IgD⁺, CD27⁻, MTG⁺, CD24⁻, CD21⁻, CD38^lo, CD23⁻) was identified as an important and persistent precursor of circulating ASCs during SLE flares. Up to 32.5% of acN sequences share clonal identity with co-circulating ASCs; 9 of 10 largest acN clones are direct ASC precursors. The average memory-to-naive ASC connectivity ratio is significantly lower in SLE than in vaccination responses, confirming that naive B cell recruitment — not memory recall — is a dominant feature of SLE flare ASC expansion (see Tipton2015 - ASC Diversity and Origin in SLE, NGS of sorted populations, n=5 SLE acute flare).

  • Germline-encoded autoreactivity without SHM proves EF differentiation: ASC clone 652-F6 had zero mutations in both VH and VL regions yet displayed strong reactivity to ANA, dsDNA, chromatin, and ribosomal P antigens. This is definitive proof that naive B cells can differentiate into autoreactive ASCs via EF pathways without any GC transit or SHM-driven affinity maturation (see Tipton2015 - ASC Diversity and Origin in SLE, single-cell monoclonal antibody analysis).

  • Low SHM as an EF biomarker in peripheral blood: ASCs in SLE flares show substantially lower VH mutation rates (avg 4.98%) than post-vaccination ASCs (avg 7.33%). Approximately 30–33% of SLE ASC sequences contain <3% VH mutation vs. ~10–12% post-vaccination. This <3% mutation fraction is the most quantitatively precise available benchmark for EF-derived plasmablasts in human peripheral blood (see Tipton2015 - ASC Diversity and Origin in SLE).

  • acN cell persistence sustains EF output over months: acN cells persist in circulation for months, continuously seeding new ASC progeny. Single-cell analysis confirmed clonal identity between acN cells and ASC clones detected by NGS 4 months earlier. Phylogenetic trees show unmutated acN precursors (0% SHM) co-existing with ASC progeny carrying up to 21.5% VH mutation, implying prolonged diversification from a long-lived EF-activated naive precursor (see Tipton2015 - ASC Diversity and Origin in SLE).

  • EF response in SLE produces polyclonal, bystander-activated ASCs alongside autoreactive expansions: ELISPOT showed that influenza- and tetanus-specific memory ASCs are spontaneously activated in SLE flares despite no recent immunization — evidence of broad bystander polyclonal activation of memory alongside selective clonal expansion of autoreactive naive cells (see Tipton2015 - ASC Diversity and Origin in SLE).

  • Human EF differentiation pathway proposed from cross-sectional and in vitro evidence: rNAV → aNAV → DN2 → plasmablast. Jenks2018 integrates phenotypic, transcriptional (RNA-seq), epigenetic (ATAC-seq), functional (in vitro), and repertoire (BCR sequencing) evidence to define the full pathway. No in vivo lineage tracing has been performed; the trajectory is inferred from population-level data and in vitro differentiation using supraphysiological stimuli. Key signals: TLR7 + IFN-γ + IL-21 drive each transition; CD40L and IL-4 inhibit it. The pathway operates without BCR stimulation or extensive cell division. Each step is confirmed by clonal connectivity (shared BCR sequences between aNAV, DN2, and PC in vivo) (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, cross-sectional + in vitro + multi-omic).

  • DN2 cells are the EF pre-plasmablast: DN2 B cells (IgD⁻CD27⁻CXCR5⁻CD21⁻CD11c⁺CD19^hi) are poised PC precursors with high IRF4, BLIMP-1, and open PRDM1 chromatin by ATAC-seq. DN2 cultures generate ASC frequencies comparable to SWM by ELISPOT, despite requiring only TLR7 + IL-21 + IFN-γ (no BCR engagement). Notably, DN2 cells generate plasmablasts without BCR cross-linking — the mechanistic basis for bystander activation of non-antigen-specific B cells. This establishes DN2 as the immediate precursor of EF-derived plasmablasts (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • TLR7 hyper-responsiveness is the mechanistic engine of EF activation: DN2 and aNAV cells show enhanced pERK and pMAPKp38 phosphorylation after R848 (TLR7 agonist) stimulation compared with rNAV, SWM, and DN1. This hyper-responsiveness correlates with low expression of the negative TLR regulator TRAF5 and low TNFAIP3 (A20) — a plausible mechanism, though no rescue experiment (TRAF5 overexpression) has been performed to establish causality. Concurrently, CD40L stimulation fails to activate DN2 cells (no CD25 upregulation), consistent with a T cell-independent activation mode. This dual phenotype — TLR7-hyper-responsive, CD40L-unresponsive — is the functional signature of EF pathway cells (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, phospho-flow + RNA-seq).

  • Transcriptional programme of EF effectors: DN2/aNAV cells express T-bet (TBX21) + ZEB2 (which cooperate to repress TCF7), high IRF4 + low IRF8 (promoting PC differentiation), and BLIMP-1 (PRDM1), while lacking the repressor cassette BACH2/FOXP1/FOXO1/BCOR that maintains the resting/memory state. This transcriptional programme is distinct from GC-derived SWM cells (which express TCF7/CXCR5/BACH2) and from DN1 cells (which share the SWM transcriptome) (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, RNA-seq of sorted populations).

  • CD40L inhibits EF differentiation but not GC pathway: In vitro, CD40L stimulation inhibits rNAV differentiation into aNAV and DN2 but does not affect DN1 generation. This is the most direct evidence that GC (CD40-dependent) and EF (TLR7-dependent) pathways are not merely different stages of the same process but are antagonistically regulated (see Jenks2018 - DN2 B Cells and EF Pathway in SLE, in vitro differentiation).

  • Competing EF vs. GC endotypes predict clinical outcomes: SLE patients segregate into EF-dominant and memory/GC-dominant clusters by B cell profiling. ~75% of patients fall into EF or memory endotypes; higher severity and nephritis concentrate in the EF cluster. EF endotypes also predict reduced affinity maturation and neutralizing activity of SARS-CoV-2 mRNA vaccine responses in SLE patients (see Sanz2025 - Human Atypical B Cells Overview, review citing Jenks et al. 2021, Faliti et al. 2024).

  • EF responses associated with worse cancer outcomes: A large single-cell analysis of human tumors found EF responses associated with worse clinical outcomes and resistance to immunotherapy, promoted by an immunosuppressive T cell environment. This extends the EF endotype concept beyond autoimmunity and infection into cancer (see Sanz2025 - Human Atypical B Cells Overview, review citing Ma et al. 2024).

  • Self-limited EF autoreactivity observed in primary SARS-CoV-2 infection: Healthy subjects generate naïve-derived DN2 cells producing dual-reactive (virus + self) antibodies with low or no SHM during primary SARS-CoV-2 infection. These autoreactive responses subside within months in healthy individuals — constituting self-limited EF autoreactivity. Whether this extends to routine infections or is specific to the severe inflammatory milieu of COVID-19 is untested. In genetically predisposed individuals (SLE), these responses may become perpetuated through elevated interferons, BAFF, IL-21, genetic susceptibility variants, and environmental factors (see Sanz2025 - Human Atypical B Cells Overview, review — council rated generalizability as WEAK).

  • GC-independent autoimmunity confirmed by monogenic evidence: TLR7 gain-of-function mutations cause human SLE with expanded ABC/DN2 in a B cell-intrinsic, GC-independent fashion. In mice, the orthologous mutation induces lupus without GC involvement. Additional mutations enhancing TLR function (NOX2 loss-of-function, UNC93B1 instability) also drive ABC/DN2 expansion (see Sanz2025 - Human Atypical B Cells Overview, review citing Brown et al. 2022).

  • ZEB2 as primary driver, repressing GC entry: B cell-intrinsic Zeb2 is essential for the ABC transcriptional programme. Zeb2 represses Mef2b, a TF required for GC differentiation — providing a direct mechanistic link between EF differentiation and GC exclusion. Together with the GC-independent nature of autoimmunity in TLR7 gain-of-function mice, this establishes the molecular basis for EF/GC antagonism (see Sanz2025 - Human Atypical B Cells Overview, review citing Dai et al. 2024).

  • EF pathway in HIV: In HIV, AtB cells localise to extrafollicular areas of lymph nodes in the context of disorganised GCs, adding chronic HIV to the list of infections with dominant EF responses. A similar phenomenon occurs in lymph nodes and spleen of patients with lethal COVID-19 (see Sanz2025 - Human Atypical B Cells Overview, review).

  • First demonstration of EF pathway in acute human viral infection (COVID-19): Critically ill COVID-19 patients (CoV-A cluster) displayed hallmarks of EF B cell activation phenotypically similar to active SLE (n=7 SLE comparators — limited for equivalence claims): expanded aN and DN2 cells, elevated DN2:DN1 ratios (P ≤ 0.0001 vs. HD), massive ASC expansion with CD138⁺ enrichment, contraction of unswitched memory cells, and a chemokine receptor shift from CXCR5 (follicular homing) to CXCR3 (IFN-γ-inflamed tissue homing). Hierarchical clustering of B cell population frequencies separated ICU from outpatients almost perfectly, driven by coordinated aN + DN2 + DN3 + ASC expansion (see Woodruff2020 - EF B Cell Responses in COVID-19, 24-marker spectral FCM, n=10 ICU-C, n=7 OUT-C, n=17 HD, n=7 SLE).

  • Central paradox: functional neutralizing antibodies + poor outcomes: CoV-A patients (n=3–4 with neutralization data) produced the highest anti-SARS-CoV-2 RBD antibodies (all isotypes) with confirmed in vitro neutralization by day 5 post-symptom onset — yet had the worst clinical outcomes (ICU, death). This suggests that EF-derived ASC responses can produce functional protective antibodies while simultaneously correlating with disease severity. The paradox challenges the assumption that antibody quantity/quality determines protection, and raises the possibility that the EF pathway itself — or its inflammatory accompaniments (IL-6, IP-10, CRP) — contributes to pathogenesis (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • ASC repertoire in COVID-19 consistent with EF origin (n=1 patient — not generalizable): Single-cell V(D)J of ASCs from a single CoV-A patient showed >50% germline (unmutated) VH clonotypes, balanced IgM/IgG1/IgA1 with ongoing class switching, and enriched autoreactive VH4-34 clones with preserved FR1 patches. This repertoire signature — newly recruited, germline-dominant, with defective tolerance — matches the EF ASC fingerprint established in SLE by Tipton2015. However, this derives from a single patient’s repertoire; generalizability to the broader CoV-A cluster is unestablished (see Woodruff2020 - EF B Cell Responses in COVID-19, 10x Chromium scV(D)J, 2,017 clonotypes, n=1 patient).

  • DN2 expansion as a cellular correlate of inflammatory severity: DN2 frequency within the DN compartment correlated with CRP (r² = 0.39, P = 0.022), which in turn correlated with IL-6 and IP-10. Both IL-6 and IP-10 — previously identified as biomarkers of COVID-19 severity and the cytokine environment that drives EF responses in SLE — were elevated in the CoV-A cluster (see Woodruff2020 - EF B Cell Responses in COVID-19).

  • Validated by histopathological evidence of GC suppression: Post-mortem tissue analysis showed complete absence of germinal centers in COVID-19 lymph nodes and spleens, with preservation of AID⁺ B cells diffusely distributed outside GC structures and IgD⁻CD27⁻ DN B cells present at both follicular and extra-follicular sites with T-B conjugates. The specific block was in Bcl-6⁺ GC-TFH differentiation, with aberrant TNF-α accumulation implicated as the mediator. This tissue evidence supports that the peripheral EF dominance reflects actual GC failure — the EF pathway is not simply faster, it may be the only pathway available when GCs are suppressed (see Kaneko2020 - GC Loss and TFH Block in COVID-19, n=11 COVID + controls, multi-color immunofluorescence; see also Woodruff2020 - EF B Cell Responses in COVID-19).

  • EF expansion is antigen-driven, not bystander: Dual-fluorophore RBD probe staining of peripheral blood B cells showed SARS-CoV-2-specific cells within all disease-related populations — activated naive, DN2, DN3, switched memory, and plasmablasts. This confirms that the coordinated EF B cell expansion observed by Woodruff2020 in the blood compartment is an antigen-directed immune response, not a non-specific inflammatory epiphenomenon. DN2 and DN3 were CXCR5-low (extrafollicular); DN1 and DN4 were CXCR5-high (follicular). Switched memory cells constituted the largest RBD⁺ subset (53.6% convalescent, 39.1% severe) (see Kaneko2020 - GC Loss and TFH Block in COVID-19, 13-color flow cytometry + dual-fluorophore probes, n=68 blood cohort).

  • GC failure is a lymphocyte differentiation block, not stromal destruction: Follicular dendritic cell (FDC) networks were preserved in COVID-19 lymphoid tissue despite complete GC absence. This establishes that GC loss is not due to destruction of the architectural scaffold but rather to a specific failure in Bcl-6⁺ GC B cell and GC-TFH differentiation — implicating aberrant cytokine milieu (TNF-α, TH1 skewing) rather than tissue damage as the mechanism (see Kaneko2020 - GC Loss and TFH Block in COVID-19, multi-color immunofluorescence, CD35⁺ FDC staining).

  • Naive and transitional B cell consumption parallels EF expansion: In the peripheral blood cohort, total CD19⁺, naive, early transitional (T1/T2), and follicular B cells were markedly reduced in severe COVID-19, correlating with CRP, symptom duration, and hospitalisation length. This depletion of upstream B cell compartments concurrent with massive downstream EF output (aN, DN2, DN3, PB expansion) is consistent with accelerated consumption of naive/transitional precursors by the EF pathway under inflammatory conditions (see Kaneko2020 - GC Loss and TFH Block in COVID-19, n=68 blood cohort).

  • EPIGENETIC HIERARCHY CONFIRMS EF DIFFERENTIATION PATHWAY: Integrated RRBS, ATAC-seq, and RNA-seq of 5 sorted B cell subsets from SLE patients and healthy controls established a linear differentiation trajectory: resting naive → T3 → activated naive → DN2/switched memory → ASC. DNA methylation phylogenetic analysis placed DN2 closest to ASC in both SLE and HC, confirming its position as the most terminally differentiated non-ASC subset. DN2 and aN cells were epigenetically closer to each other in SLE than in healthy controls, supporting accelerated differentiation through the aNAV→DN2 axis in SLE (see Scharer2019 - Epigenetic Programming in SLE B Cells, n=9 SLE + n=12 HC, African-American females).

  • SLE disease signature present in resting naive B cells — epigenetic priming of the EF pathway: 6,664 differentially methylated loci stratified all SLE vs. healthy samples. Resting naive B cells in SLE already showed 564 DMLs, 612 DEGs, and 402 DARs vs. HC, including upregulated NR4A1 (BCR-induced) and NR4A3 (TLR-induced) — indicating resting naive cells in SLE have received both BCR and TLR stimulation. This SLE signature propagated through all downstream subsets, demonstrating a transmissible epigenome that modulates the activation threshold for EF differentiation (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • Separate epigenetic programmes for EF vs. GC endpoints: DN2 (EF endpoint) accessible chromatin was enriched for T-BET, AP-1, and EGR motifs; isotype-switched memory (GC endpoint) was enriched for NF-κB, EBF, and OCT2 motifs. Despite similar DNA methylation states, these populations have fundamentally different chromatin architectures — confirming they represent distinct differentiation pathways, not different stages of the same pathway (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • T-BET programme is normal; AP-1/EGR amplification is disease-specific: T-BET motif enrichment in DN2 chromatin was shared by healthy controls and SLE — it is a normal feature of DN2 differentiation. AP-1 and EGR motif accessibility was amplified in SLE aN and DN2 cells beyond healthy levels, identifying AP-1/EGR as the disease-specific epigenetic layer that enhances EF differentiation in pathological immune environments (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • ATF3 as a key EF regulator in disease: ATF3 — induced by BCR/TLR stimulation and cellular stress — was the top SLE-specific transcription factor in the DN2 network. Its 98 target genes map to MTORC1, G2/M checkpoint, apoptosis, UPR, and TNF signalling pathways. ATF3 heterodimerises with Jun family members (all upregulated in SLE DN2) to function as an activator, potentially explaining the metabolic and proliferative programme of EF effector cells (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • DN2 cells resist apoptosis: GSEA showed all SLE B cell subsets except DN2 were enriched for G2/M checkpoint and apoptosis pathways. This unique negative enrichment in DN2 cells may explain their selective expansion in SLE — and potentially in any disease with EF activation (see Scharer2019 - Epigenetic Programming in SLE B Cells).

  • ALTERNATIVE LINEAGE FRAMEWORK CHALLENGES THE PRE-PLASMABLAST MODEL OUTSIDE SLE: scRNA-seq of >12,000 B cells from malaria-exposed and non-exposed donors defined an “alternative lineage” (atBC1, atBC2, atBC3, MBC1) characterised by TBX21, ITGAX (CD11c), and FCRL5 — overlapping with the DN2 phenotype. Critically, no atBC cluster upregulated PC maintenance genes (XBP1, IRF4, PRDM1/BLIMP-1), and PCs were detached from the pseudotime manifold with no intermediate bridging population. All non-naive clusters showed significant SHM, consistent with post-GC origin. Sutton’s own Discussion reconciles this with Jenks2018: in SLE, chronic TLR7 stimulation can drive atBCs toward PC fate, but in healthy, vaccination, and infection contexts they are an alternative memory lineage rather than obligate pre-plasmablasts. This reframes the EF DN2→PB pathway as context-dependent — operative in pathological TLR7-high environments (SLE, possibly severe dengue) but not a default property of the T-bet⁺/CD11c⁺ lineage (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium + Smart-seq2 + CITE-seq, 4 cohorts).

  • CD21⁻CD27⁻ gating captures only ~45% of transcriptomic alternative lineage cells: CITE-seq data demonstrate that the conventional DN gate — used in all prior flow cytometry studies of EF B cells — misses the majority of transcriptomically-defined alternative lineage B cells. CD11c protein is a superior single marker. This implies EF/alternative lineage cells have been systematically undercounted in COVID-19, dengue, and SLE studies that rely on CD21⁻CD27⁻ gating (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, CITE-seq).

  • Alternative lineage present at ~20% of B cells in healthy donors: Transcriptomic clustering identified alternative lineage cells in non-exposed Australian donors at ~20% of total B cells — far above the ~5% typically reported by CD21⁻CD27⁻ flow cytometry. The alternative lineage is therefore a substantial normal component of the B cell repertoire, present at baseline in healthy donors. However, presence does not establish non-pathological function — whether these cells have the same functional programme in health vs. disease contexts remains unclear. This challenges the implicit assumption that EF-phenotype B cells are exclusively disease-associated (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium; validated by flow cytometry n=18).

  • MBC1 cluster provides transcriptomic evidence for alternative lineage memory: A quiescent MBC1 cluster at the base of the alternative lineage pseudotime branch expresses memory markers without activation markers — the first transcriptomic evidence for a “memory DN2” population, confirming predictions from Sanz2025 and Faliti2024 (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4, 10x Chromium).

  • Vaccination primes the alternative lineage: PfSPZ vaccination (n=15) and influenza vaccination (n=9) both activate alternative lineage B cells, with repeated boosting progressively shifting cells toward CD21⁻CD27⁻ surface phenotype. This establishes that the alternative lineage participates in normal vaccine responses, extending its relevance beyond autoimmunity and chronic infection (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection).

  • LANDMARK: First direct demonstration of somatic hypermutation at extrafollicular sites in vivo. In MRL/lpr lupus-prone mice, rheumatoid factor (RF) B cells carrying a transgenic VH chain proliferated at the splenic T zone–red pulp border — not in GCs — in clusters interdigitated with T cells and CD11c⁺ dendritic cells, completely lacking FDC networks. Microdissection of these clusters followed by Vκ8 PCR and sequencing revealed extensive somatic mutations organised into genealogical trees (shared trunk + unique branch mutations), the definitive signature of ongoing in situ SHM. The mutation rate was estimated at ~0.3 mutations per gene per generation — comparable to GC hypermutation. In the same spleens, Id⁻ GCs contained few or no RF B cells and yielded no mutated Vκ8 sequences; some mice with active EF mutation had no GCs at all. This eliminates GC transit as a requirement for SHM and establishes the EF T zone–red pulp border as a bona fide site of antibody diversification (see William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice, in vivo murine model, 8 mice, 305 sequences from 45 microdissected libraries).

  • EF mutation may escape GC tolerance checkpoints. William2002 proposes that SHM normally occurs within GCs because these structures provide the censoring mechanisms (FDC-mediated selection, Fas-dependent apoptosis) that eliminate autoreactive mutants. When mutation occurs at EF sites — where FDCs are absent and (in lpr mice) Fas-mediated apoptosis is defective — these tolerance checkpoints are bypassed, allowing autoreactive B cells to survive and diversify. This tolerance escape mechanism is directly relevant to the autoreactive VH4-34/VH1-69 enrichment in dengue plasmablasts (Appanna2016) and the transient self-limited EF autoreactivity model (Sanz2025) (see William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice).

  • TLR co-stimulation as a unifying mechanism for EF B cell activation in autoimmunity. William2002 invokes Leadbetter et al. (2002, Nature) showing that chromatin-containing immune complexes co-stimulate RF B cells via TLR9. The authors propose that TLR co-signalling may be a general feature of dominant autoantigens that enables sustained EF proliferation and mutation. This TLR9 mechanism in the RF system is the direct precursor to the TLR7 pathway established by Jenks2018 for human DN2 cells and proposed by GodoyLozano2016 for dengue EF B cells — different TLRs sensing different ligands (chromatin vs. ssRNA) but driving analogous EF outcomes (see William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice).

  • EF is the generating pathway for the DN subsets, but not for all of the ABC superset — origin is the key ABC↔DN distinction. Among the DN subsets, DN2 and DN3 are the ones strongly tied to extrafollicular responses; the ABC population, by contrast, is commonly thought to be at least partly GC-experienced (diverse SHM⁺ repertoire), though homeostatic and EF routes are not excluded. The shared differentiation requirements — TLR7/9 + IFN-γ and/or IL-21 (IFN-γ→T-bet, IL-21→CD11c) — are the same programme this wiki builds from Jenks2018/Woodruff2020, with the murine ABC literature (Hao2011, Rubtsov2011) as the comparative backbone. Origin (EF-tied DN vs. GC-experienced ABC) is therefore one of the axes on which the two labels diverge even where their phenotype overlaps (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Cancro 2020 / Jenks 2018 / Naradikian 2016).

  • ★ THE PRE-GC BRANCH POINT IS TRIPOTENT — and the wiki’s EF effector is only one of its three outputs. Activated B cells at the T–B border form “activated precursors” (APs) coexpressing naive/memory markers (CD38, CCR6) and activated/GCBC markers (CD95, GL7), with intermediate IRF4 and absent/low BCL6. Limiting-dilution transfer shows a single naive B cell can generate all three lineages: early plasma cells (ePCs), early memory B cells (eMBCs), and GC B cells. The three-way split is evident by day 4 post-immunization (see Glaros2025 - Multilayered Identity of B Cell Memory, review, no original data, citing mouse single-cell transfer). This is the correct frame for the wiki’s EF pathway: the aNAV→DN2→plasmablast arm maps onto the ePC/effector limb, not onto eMBC. “GC-independent” is the branch; “extrafollicular effector” is one of its outputs. Conflating them would inflate the apparent support for the wiki’s EF claims — see Memory B Cell Contradictions.

  • ★ Affinity and signal strength set the branch, and they favour the effector limb at high affinity. Higher-affinity BCRs and stronger T-derived signals favour ePC generation; lower-affinity antigen more often yields eMBCs; and increased antigen availability or anti-CD40 during the early response shifts the early activated compartment toward the ePC lineage. GCBC fate, unlike PC fate, cannot be induced by simply changing stimulus strength — it requires a more complex regulatory framework, and interruptions in CD40–CD40L signalling (rather than signal strength per se) may bias toward GCBC (review, mouse). Note this is the opposite directionality from the SLE EF model in this wiki, where DN2→PC proceeds on TLR7+IL-21+IFN-γ without BCR stimulation (Jenks2018 - DN2 B Cells and EF Pathway in SLE) — a genuine difference between physiological (antigen-affinity-driven) and pathological (innate-signal-driven) routes to the same effector output.

  • ★ GC-independent generation of the atypical cluster now has direct fate-mapping evidence. GC-specific genetic fate mapping in mice shows that after acute viral infection, the majority of antigen-specific ABCs are generated via a GC-independent pathway (see Glaros2025 - Multilayered Identity of B Cell Memory, review, citing Song 2022, mouse). This is the strongest external support the wiki holds for its central premise that the atypical/DN cluster is EF-generated — and it directly qualifies the Lamprinou2026 - ABCs and DN B Cells bullet above, which reports ABCs as “commonly thought to be at least partly GC-experienced.” Fate mapping assigns origin directly rather than inferring it from SHM/repertoire, so it outranks that inference. Caveats the review carries and the wiki must keep: one murine acute viral model; generalization to other ABC-generating contexts (notably the chronic settings where ABCs were first described) “remains to be elucidated.”

  • GC-independent memory is demonstrable in humans, though not quantified. Patients with CD40L deficiency and mice lacking BCL6 in the haematopoietic compartment — neither capable of functional GCs — still generate detectable MBC populations; early antigen-specific, largely unswitched MBC-phenotype cells appear before the first GC B cells form (see Glaros2025 - Multilayered Identity of B Cell Memory, review). This establishes existence in humans; it does not establish the numerical dominance that mouse fate mapping shows.

  • Extrafollicular SHM/CSR machinery — a caution that cuts against over-reading fate maps. Many tissue-B-cell studies infer GC origin from Aicda-based fate mapping, but AID-driven CSR and SHM also occur outside the GC, so these systems do not establish GC provenance (review). This independently restates the wiki’s existing position from William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice and Kaneko2020 - GC Loss and TFH Block in COVID-19, and extends it to a whole literature (tissue-resident memory) the wiki had not previously examined — see Tissue-Resident Memory B Cell.

  • A GC-absent infection model produces tissue-resident, somatically hypermutated T-bet⁺ B cells. In murine Ehrlichia muris infection — GCs absent in the spleen — somatically hypermutated IgM⁺T-bet⁺ MBC-like cells are generated GC-independently and reside in liver and spleen, persisting after clearance (see Glaros2025 - Multilayered Identity of B Cell Memory, review, mouse). A clean demonstration that the EF/GC-independent route can produce durable, mutated, T-bet⁺ cells in a non-autoimmune infection.

  • ★ GC entry by ABCs “has not yet been directly demonstrated” — Cancro’s explicit 2020 position, years before the wiki’s fate-mapping evidence. T-bet⁺ B cells express PNA and CD95, but “anatomic localisation of ABCs in GCs has never been shown,” and somatic hypermutation can occur independent of GC formation (citing Di Niro et al. 2015, Immunity — Salmonella infection driving promiscuous B cell activation followed by extrafollicular affinity maturation; plain text, no wiki page). Conclusion, in the author’s own words: “it remains possible that ABCs arise and undergo somatic hypermutation in extrafollicular or other GC-independent niches” (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse). This is the field’s canonical ABC review — written by the investigator who co-defined the subset — taking the EF possibility seriously five years before the fate-mapping evidence the wiki now carries via Glaros2025 - Multilayered Identity of B Cell Memory (Song 2022) and Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection.

  • ⚠ This is a GC-origin claim about the ABC/atypical cluster generally, not a claim about this page’s EF effector pathway specifically — do not conflate the two. Per the tracked distinction under Contradictions & Debates below, the “extrafollicular or GC-independent niches” language describes where ABCs may arise and hypermutate as a population, which is closer to the origin/memory question than to the proliferative, ASC-generating DN2→plasmablast effector programme this page otherwise documents. Read alongside, not as a restatement of, the aNAV→DN2→plasmablast evidence above.

  • A second extrafollicular infection precedent: IgM⁺CD11c⁺ splenic plasmablasts drive CD4-T-independent antibody responses in murine Ehrlichia. Racine et al. 2008 (J Immunol; plain text, no wiki page) described IgM⁺CD11c⁺ extrafollicular splenic plasmablasts responsible for CD4-T-independent antibody responses during Ehrlichia muris infection, alongside protective T-bet⁺ memory B cells that are multipotential on serial adoptive transfer. This is an independent murine EF-plasmablast precedent alongside the RF/lupus EF-SHM system already documented above (William2002 - Extrafollicular Somatic Hypermutation in Autoimmune Mice) (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse).

  • The two-signal ABC differentiation programme as the murine mechanistic backbone for this page’s EF pathway. TLR7 or TLR9 poises a naive B cell for ABC fate; poising must be followed by IFN-γ or IL-21 to complete differentiation; BCR ligation alone or with CD40 costimulation does not enable the fate, though it synergises with TLR signalling for proliferation; both requisites are cell-intrinsic (coculture-proven). T-bet expression begins within 12 h, before the first division (see Cancro2020 - Age-Associated B Cells, review — no original data; mouse, in vitro + in vivo). This murine two-signal system is the mechanistic precedent underlying the human TLR7+IFN-γ+IL-21 EF differentiation programme this page documents from Jenks2018 - DN2 B Cells and EF Pathway in SLE.

  • ★ Review-level statement of the GC-independent case for DN2/DN3 — four independent lines, none decisive alone. A 2023 survey of DN origins assembles the EF case as: (i) the majority of DN and switched-memory cells are clonally distinct, with different IgV(D)J family and gene usage, pointing to different activating pathways or different stimulating antigens; (ii) DN2 cells lack CXCR5 and CD62L, both required to enter lymphoid follicles; (iii) DN2 shares transcriptome, phenotype and expanded clones with activated naive B cells; (iv) aNAV cells differentiate into DN2 in vitro under TLR7 ligand + IFN-γ + IL-21. The review nonetheless files this as a hypothesis, not a result: “these hypotheses suggest that DN1-3 cells have different origins although conclusive evidence is still lacking” (see Beckers2023 - Origins and Functions of DN B Cells, review, own AIRR data + citing Jenks 2018).

  • The EF pathway is set alongside two GC-dependent alternatives, not asserted over them. The competing origins are premature exit from the GC reaction (proposed for DN1, on the basis of CXCR5 expression and a mutation load intermediate between naive and switched memory) and descent from switched memory via CD27 downregulation under chronic antigen stimulation. Different DN subsets are proposed to take different routes — so “the DN compartment” as a whole has no single generating pathway (see Beckers2023 - Origins and Functions of DN B Cells, review; see Double-Negative B Cell, Germinal Center).

  • ⚠ The strongest challenge to a clean EF/GC split: DN1 also makes ASCs. GC-dependent DN1 cells differentiate into ASCs in vitro under the same TLR7 + BCR + IFN-γ + IL-21 cocktail that drives DN2→PB, and whether DN1’s route is TLR7- or BCR-dependent is unresolved. Class-switching and somatic hypermutation are separately noted to occur outside follicles. The EF pathway is therefore better described as the route that predominates for DN2/DN3 than as a pathway with exclusive access to ASC output (see Beckers2023 - Origins and Functions of DN B Cells, review, citing Jenks 2018).

  • EF-associated DN expansion is documented across a wide disease range — and dengue is not in it. Review-level tabulation covers ~25 conditions including six infections (meningitis/encephalitis, acute sepsis, malaria, rotavirus, HIV, COVID-19) and vaccination against influenza and tick-borne encephalitis. Dengue does not appear anywhere in the review. See Why DN B Cells Matter - Disease Relevance and Infectious Disease Case (see Beckers2023 - Origins and Functions of DN B Cells, review, Table 1).

  • ★ “Extrafollicular” now names at least four distinguishable situations, and the wiki’s human evidence base sits in the weakest of them. A twelve-author consensus Perspective taxonomises current usage: (1) the original anatomical definition — proliferating B cell and plasmablast foci in splenic bridging channels/red pulp or LN medullary cords after immunisation, peaking days 4–6; (2A) infection with lymphoid architecture disruption (Salmonella, Leishmania, Ehrlichia, Plasmodium, LCMV, Borrelia), where inflammation obscures follicle demarcation so that “outside the follicle” is partly an artefact of not being able to see the follicle; (2B) infection without architecture disruption (influenza, SARS-CoV-2), giving T-dependent, GC-independent, high-avidity, long-lived responses in intact lymph nodes where the site of selection is simply unknown; (3) chronic T-dependent activation inferred from low Ig mutation load (autoimmunity, persistent infection, Peyer’s patches, tonsil); and (4) phenotypically defined B cells in blood or non-lymphoid tissue, with no location data at all. Situation 4 is where every human study in this wiki sits, dengue included (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • ★ The location claim and the origin claim must be separated — only the origin claim is inferable from blood. The Perspective’s central corrective, applied by name to the human DN2 cell: GC-independent derivation is suggested by severe-COVID tissue studies and lupus-nephritis kidney biopsies, but “direct visualization of EF foci with DN2 cells in the splenic bridging channel or LN medullary cords has not been done,” and such cells “may emanate from reactions in other non-classical EF sites (e.g., T-B border, etc.).” Conclusion: “the EF designation of this human DN2 cell refers to its presumed GC-independent origin rather than its location” (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data). This wiki now holds the distinction as a standing concept — see GC-Independent Response, which carries the evidence-to-claim mapping.

  • ★ No flow cytometry panel alone can identify an EF B cell. “Currently there are no flow cytometry-based means alone that can distinguish EF B cells nor their progeny from activated cells in earlier phases. Few if any markers exist that define EF B cells in the absence of tissue imaging of antigen-specific B cell proliferation outside of a follicle.” Absence of CXCR5, low SHM, low BCR affinity and IgM isotype are each non-definitive because each occurs on cells that did participate in a GC. Further, CD21^lo / CXCR5⁻ / CD11c⁺ may report recent activation rather than a permanent state (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • The original EF description already contained the features later assumed to be GC-exclusive. The founding hapten-immunisation studies showed EF responses producing IgM and IgG, and contributing to long-lived PC and memory compartments; higher-affinity BCRs preferentially expanded at EF sites through increased proliferation and reduced apoptosis after competing for early T help. The later shorthand — that EF means low-affinity, transient, short-lived IgM to T-independent antigens — is described as “not consistent with the original descriptions” (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • A four-phase spatiotemporal framework is proposed in place of a unified definition. Phase 1: BCR engagement in the follicle, with signal 2 from T cells, TLR ligands, or complement. Phase 2: relocation within ~6 h to the T-B border / IFZ / subcapsular sinus / inner MZ (↑EBI2, ↑CCR7, ↓CXCR5, ↓S1PR1) and proliferation there for a few days. Phase 3: divergence into GC (↓EBI2, ↓CCR7, ↑S1PR2/P2RY8) versus GC-independent blast and plasmablast growth (↑CXCR4, no S1PR2, ↓↓CXCR5, EBI2-dependent migration to bridging channels and red pulp). Phase 4: output — both arms generate plasmablasts, memory, and short- and long-lived plasma cells, differing in kinetics and relative contribution (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • Consensus was reached on exactly one boundary: EF responses do not include B cell responses at non-lymphoid sites. Responses in inflamed peripheral tissue, however GC-independent, are outside the term (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • ★ [2026-08-27] A flagship “extrafollicular” paper that never establishes an extrafollicular location — and a clean illustration of why the wiki now separates the two claims. The title of Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues reads “Extrafollicular IgD⁻CD27⁻CXCR5⁻CD11c⁻ DN3 B cells infiltrate inflamed tissues…”, but the paper performs no follicular-versus-extrafollicular quantification anywhere: anti-Bcl6 (clone LN22) appears in its immunofluorescence antibody list and no Bcl6 result is reported. Its tissue findings are in lung parenchyma and salivary gland, where “extrafollicular” is a category error — a B cell in a salivary gland is trivially outside a follicle, and tissue infiltration is not participation in an extrafollicular focus in a secondary lymphoid organ. “Extrafollicular” here is a presumed-origin label, exactly as Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses predicted the field would use it. The strongest GC-independence argument for these lymph nodes is by exclusion — Kaneko2020 - GC Loss and TFH Block in COVID-19 found loss of Bcl-6⁺ Tfh and germinal centres in the same autopsy cohort — and that argument belongs to Kaneko, not here (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=6 autopsy). See GC-Independent Response.

  • ★ [2026-08-27] The cells the EF literature calls its effectors are not the ones found in inflamed tissue. Across two diseases, DN2 was scarce in tissue (~7 cells/mm² in COVID-19 thoracic lymph node against DN3’s ~400; ~3% of the IgG4-RD salivary-gland DN pool) while DN1 and DN3 dominated. Total DN infiltration was significant in both diseases (lung ~29% vs ~11% of B cells, p<0.05; salivary gland ~35% vs ~16%, p<0.05). If the EF pathway’s tissue-resident output is DN3 rather than DN2, then blood DN2 frequency — the wiki’s principal EF readout — may be measuring the pathway’s transit population rather than its effector pool (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=6–10 per tissue arm; subset-level panels carry no significance markers).

  • [2026-08-29] The effector axis grades with systemic involvement rather than switching on with a diagnosis. In a 207-patient lupus-spectrum cohort, the full effector signature — activated naive, DN2, DN3 and plasmablast expansion with unswitched-memory contraction and reversal of DN1 predominance — was present in primary skin-limited cutaneous lupus as well as in SLE, at lower magnitude. More pointedly, within SLE the presence of cutaneous disease tracked with lower DN expansion, which the authors tie to the reduced rate of lupus nephritis in that subgroup (see Jenks2021 - B Cell Subset Composition in Cutaneous Lupus, n=207 + 46 healthy controls, cross-sectional). ⚠ Blood phenotype only; under the [2026-08-27] decision this supports a GC-independent effector reading, not a claim about anatomical location — no imaging was performed.

  • [2026-08-29] Roughly half of skin-limited lupus patients have no effector signature at all. Unsupervised clustering placed 42% of primary CCLE patients (48% by the Discussion’s count) in the healthy-donor clusters, versus only 15–16% of SLE patients. The effector/EF phenotype is therefore a patient-stratum property, and the authors propose it may mark those at risk of systemic progression — a hypothesis this cross-sectional design cannot test (see Jenks2021 - B Cell Subset Composition in Cutaneous Lupus).

  • ★ Tfh deliver help at the follicular edge, and the position was imaged rather than inferred. Confocal microscopy with histocytometry at day 8 placed Tfh around B cell follicles and Th1 dispersed in red pulp, with clusters of T-bet⁺CD11c⁺ B cells at the edge of follicles adjacent to Tfh; Ripley’s multitype K function confirmed clustering with Tfh (K above the theoretical Poisson K) but random distribution relative to Th1. By day 15 the cells had relocated to the MadCAM-1⁺ marginal zone and were retained there by LFA-1 and VLA-4, shown by 3-hour in vivo blockade causing loss from spleen with a concomitant rise in blood (see Song2022 - Tfh Outside Germinal Centers Drive T-bet CD11c B Cells, mouse, LCMV-Armstrong + influenza PR8, n=3–5 mice/group). Because location is imaged here rather than deduced from blood phenotype, the [2026-08-27] wiki rule permits the extrafollicular term for this source rather than only GC-independent. ⚠ Murine spleen; no human tissue.

Dengue Context

  • FIRST DIRECT EVIDENCE OF EF B CELL ACTIVATION IN DENGUE (Ansari2025): In a prospective cohort of n=170 acute dengue adults, CD21⁻CD11c⁺ B cells within the IgD⁻CD27⁻ (DN) gate — phenotypically consistent with DN2 — are significantly expanded during acute infection. The T cell help arm is provided by Peripheral Helper T Cell (CXCR5⁻PD-1⁺), which constitute ~75% of activated CD4⁺ T cells and drive memory B cell→plasmablast differentiation via IL-21. Note: these cells are labeled “Tph” but carry a Th1 signature (CXCR3⁺, T-bet⁺, IFN-γ⁺) rather than canonical Tph markers (MAF⁺, CXCL13⁺) as defined in rheumatoid arthritis — the functional equivalence is assumed but not established. This identifies the Tph→IL-21→memory B cell→plasmablast axis as a major B cell help pathway in acute dengue, operating extrafollicularly (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, n=170 cohort + scRNA-seq + T-B coculture).

  • Neutralizing Ab paradox replicated in dengue: Anti-NS1 and anti-prM/M/E IgG are elevated in severe dengue, but FRNT₅₀ neutralizing titers do not differ between mild and severe groups. This mirrors the Woodruff2020 COVID-19 finding: EF-derived antibodies correlate with severity but not neutralization quality. In dengue, this has additional significance due to ADE — non-neutralizing cross-reactive IgG could directly enhance secondary infection (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue).

  • Concurrent EF + GC activity in dengue — tentative: Unlike the antagonistic EF/GC model from SLE (Jenks2018), acute dengue shows elevated CXCL13 alongside dominant Tph activation. However, CXCL13 is not GC-specific — Tph cells themselves are a significant source of CXCL13 (Ansari2025 scRNA-seq). Elevated CXCL13 therefore cannot be used as evidence of concurrent GC activity without independent GC markers (e.g., Bcl-6⁺ Tfh, GC B cell histology). Whether EF and GC pathways truly operate simultaneously in dengue remains unestablished (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue).

  • Memory B cells, not naive cells, are the dominant EF precursors in dengue: Tph cells preferentially drive class-switched memory B cell → plasmablast differentiation; naive B cells respond poorly. This contrasts with SLE, where naive (acN) cells are the dominant EF ASC precursors (Tipton2015). The difference likely reflects the memory recall component of dengue in an endemic setting — most patients have pre-existing cross-reactive memory from prior DENV exposure. Caveat: the coculture system used seropositive donor memory T cells, not acute-phase T cells (which died in culture), so the memory B cell preference may partly reflect the experimental system rather than in vivo biology (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, T-B coculture).

  • Tph severity association (confounded by sampling timing): CXCR5⁻PD-1⁺ Tph frequency is significantly higher in severe dengue. Combined with the severity-associated non-neutralizing IgG, this positions the Tph→EF pathway as a potential driver of immunopathology rather than protection. Caveat: severe patients were sampled later (median 8 vs 5 days post-fever-onset), potentially confounding the Tph-severity correlation — the higher Tph frequency may reflect later sampling rather than a causal severity association (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue).

  • FOUNDATIONAL: Wrammert2012 establishes the magnitude benchmark for dengue plasmablasts — IgG-dominant, short-lived, consistent with EF output: The first systematic dengue plasmablast study (n=46, Bangkok) demonstrated >1,000-fold expansion peaking at day 6–7, averaging 47% of B cells, dominated by IgG (≥70% DENV-specific), with return to baseline by 1 month and no hypergammaglobulinemia. The transient, massive, IgG-dominant response with rapid contraction is phenotypically consistent with short-lived EF-derived plasmablasts. The lack of total IgG elevation despite >10⁵ ASCs/ml implies most cells die rather than home to long-lived niches — matching the SLE short-lived PB model from Anolik2004. This paper predates the EF framework but provides the quantitative target that GarciaBates2013 severity-stratified and Ansari2025 mechanistically attributed to Tph→IL-21 (see Wrammert2012 - Plasmablast Responses in Acute Dengue, n=46 cohort, 5-color FCM + ELISpot).

  • BCR repertoire data provide intermediate SHM — not clearly EF or GC: Parameswaran2013, the first BCR sequencing study in dengue, found that convergent CDR3-bearing B cells in acute dengue carry 4.4–6.9% V gene mutation. This is intermediate between the EF benchmark (<3% per Tipton2015) and full GC maturation (~7.3%). The convergent CDR3s are more prevalent in secondary dengue and derive from memory populations using multiple V gene families. Critically, these data come from unsorted PBMCs — the SHM distribution of sorted plasmablasts specifically remains unknown. The intermediate mutation rate could reflect: (a) a mixture of EF-derived low-SHM and GC-derived high-SHM cells, (b) memory cells that initially matured in GCs and are now being recalled through the EF pathway (Tph→memory B cell per Ansari2025), or (c) EF maturation with more extensive SHM than seen in SLE. Distinguishing these models requires sorted plasmablast BCR sequencing (see Parameswaran2013 - Convergent Antibody Signatures in Dengue, 454 pyrosequencing, n=60 dengue patients).

  • MOLECULAR EVIDENCE: Low SHM in acute dengue IgG plasmablasts supports GC-independent pathway (GodoyLozano2016): HTS of IgG VH cDNA from 19 acute dengue patients revealed globally lower SHM in the acute phase vs. post-convalescence (p<0.001), with SHM paradoxically lower in secondary than primary infections and in DWS+ than DWS−. Monte Carlo simulation confirmed the acute-phase signal derives predominantly from ASCs, not memory B cells. Biased IGHV segment usage (IGHV1-2, IGHV1-18, IGHV1-69 — all innate-like “natural antibody” segments) with polyclonal CDRH3 diversity supports germline-encoded recognition rather than affinity-matured recall. The authors propose a dual-pathway model: rapid GC-independent EF differentiation producing CSR-competent but SHM-deficient IgG, concurrent with the classical GC pathway. The proposed mechanism — TLR7-mediated endosomal DENV recognition synergising with BCR crosslinking to drive T-independent CSR without SHM — directly maps onto the Jenks2018 EF pathway (TLR7 + IFN-γ + IL-21) and provides the molecular evidence for the Ansari2025 Tph-driven EF model. The low SHM in secondary infections is consistent with original antigenic sin rapidly activating germline-coded cross-reactive B cells that bypass GC maturation (see GodoyLozano2016 - Lower IgG SHM Rates in Acute Dengue, n=19 acute + n=11 post-convalescent + n=10 controls, 454 pyrosequencing, 385,206 lineages).

  • HIGH SHM IN SORTED SECONDARY PBs COMPLICATES THE PURE EF MODEL: Priyamvada2016 found that sorted plasmablasts from secondary DHF carry mean 18.1 VH mutations (~6.5% nucleotide mutation) — comparable to influenza recall and significantly higher than the EF benchmark (<3% per Tipton2015). This high SHM in sorted PBs from secondary infections, combined with GodoyLozano2016’s globally low SHM from bulk IgG, suggests a dual-pathway model: (1) memory-derived PBs with high SHM (GC-matured during prior infection, now recalled through the Tph→memory B cell axis per Ansari2025); and (2) de novo EF-derived PBs with low SHM from naive recruitment. The relative contribution of each pathway likely varies with infection history — secondary infections are more memory-dominated, while primary infections may be more EF-dominated. This offers a plausible reconciliation of the SHM paradox: the EF pathway is real (GodoyLozano2016 data) but operates alongside memory recall (Priyamvada2016 data), not instead of it. Neither paper was designed to test the dual-pathway model, which remains a working hypothesis. Evidence of Original Antigenic Sin (DENV1-biased neutralisation in DENV2 infection) further confirms that the high-SHM fraction is memory-derived, not de novo (see Priyamvada2016 - Cross-Reactive Memory Plasmablasts in Secondary Dengue, n=4 secondary DHF, 53 mAbs).

The earlier indirect dengue evidence remains relevant:

  • DENV-specific atypical MBCs (CD27⁻CD21⁻ = DN B cells) accumulate in 2° dengue durable to 18 months (Singh2026)

  • The question of whether these atypical MBCs are DN2 (EF-derived) or DN1 (GC-derived) is partially addressed by Ansari2025’s demonstration of CD21⁻CD11c⁺ EF B cells, but formal DN1/DN2/DN3 subdivision in dengue has not been performed

  • Atypical MBCs and IgM+ MBCs as potential EF memory in dengue: In 2° dengue, DENV-specific atypical MBCs (CD27⁻CD21⁻ = DN B cells) are significantly expanded, durable to 18 months, and temporally correlated with later class-switched and activated MBC levels — suggesting they participate in the anti-DENV response rather than representing exhausted bystanders. DENV-specific IgM+ MBCs are the only subset significantly elevated at the acute 2° timepoint, consistent with rapid recall from an IgM+ memory compartment. The hypothetical working model positions atypical and IgM+ MBCs as the primary early responders in 2° immunity (vs. naive B cells and IgG+ MBCs in 1° immunity), raising the possibility that repeat DENV exposure selects for EF-like memory subsets rather than conventional GC-derived memory (see Singh2026 - DENV-Specific Memory B Cell Subsets, n=4/group longitudinal — small sample but internally consistent).

  • Caveat — EF vs GC origin unresolvable with this panel: Singh2026 lacks CXCR5, CD11c, and T-bet — the markers required to distinguish DN2 (EF effectors) from DN1 (GC-derived memory) within the CD27⁻CD21⁻ gate. The atypical MBC expansion in 2° dengue is therefore compatible with either EF or GC origin, or both (see Singh2026 - DENV-Specific Memory B Cell Subsets).

  • Clonal disconnect between dengue PBs and MBCs — implications for EF pathway: Appanna2016 showed plasmablasts and convalescent DENV-binding MBCs are clonally distinct (very few shared CDR3s, all IgM). E-specific IgG⁺ memory cells selectively feed the PB compartment (85% E-specific PB mAbs), while prM/complex-epitope MBCs follow a separate trajectory. VH4-34 and VH1-69 (autoantigen-binding VH families) were found specifically in PB-derived mAbs — paralleling the VH4-34 autoreactive clone enrichment in COVID-19 EF-derived ASCs (Woodruff2020) and SLE (Tipton2015). Whether the dengue PB wave’s VH4-34 enrichment represents transient EF autoreactivity (per the Sanz2025 self-limited model) is untested (see Appanna2016 - Plasmablasts as Subset of Memory B Cell Pool, n=12 dengue, mAb cloning + VH sequencing).

  • Plasmablast magnitude as a severity biomarker in dengue (GarciaBates2013): In the earliest severity-stratified dengue plasmablast study (n=84, Recife Brazil), plasmablasts averaged 46% of B cells in severe secondary dengue (peak 87%) vs. 5% in OFI — the highest reported for any human infection at that time. Plasmablast frequency increased with both secondary infection status and disease severity. >70% of IgG-secreting plasmablasts were DENV-specific, with 3-fold preference for the infecting serotype over heterotypic serotypes. Despite this massive virus-specific output, PRNT₅₀ neutralizing titers did not correlate with plasmablast frequency — the earliest independent confirmation of the neutralizing Ab paradox in dengue, predating the Ansari2025 FRNT₅₀ data by 12 years (see GarciaBates2013 - Plasmablast Response and Dengue Severity, n=84 cohort, ELISpot + PRNT).

  • B cell activation-induced death parallels T cell pathology: GarciaBates2013 reports that B cells in severe dengue undergo Ki-67⁺ proliferation, CD69⁺/CD95⁺ activation, and active caspase-3⁺ apoptosis (up to 60% of B cells in secondary DFC), with positive Ki-67/caspase-3 correlation. This mirrors the well-described T cell activation/apoptosis in dengue and suggests that both arms of adaptive immunity undergo activation-induced cell death during severe infection. B cell numbers are maintained despite apoptosis (leukopenia is granulocyte-driven), implying high turnover consistent with an EF differentiation wave producing and consuming cells simultaneously (see GarciaBates2013 - Plasmablast Response and Dengue Severity).

  • Mechanistic divergence from SLE: Tph-dependent, not TLR7-autonomous. The Key Points from Literature section describes the EF pathway as driven by TLR7 + IFN-γ + IL-21 without BCR stimulation — the Jenks2018 SLE model where B cell activation is largely T cell-independent. In dengue, Ansari2025 demonstrates that the primary help arm is T cell-derived: Tph cells provide IL-21 to drive memory B cell→plasmablast differentiation. Whether TLR7 plays a B cell-intrinsic role in dengue EF activation (via endosomal sensing of DENV ssRNA) remains untested. The dengue EF pathway should therefore be understood as Tph-dependent until direct evidence for TLR7-autonomous B cell activation in this context is available.

  • Memory DN2 cells challenge the “short-lived output” framing: The EF response has traditionally been characterised as producing exclusively short-lived plasmablasts. However, Sanz2025 reports that antigen-specific DN2 cells persist >1 year post-SARS-CoV-2 mRNA vaccination, accounting for >50% of all spike/RBD⁺ memory cells (citing Faliti et al. 2024). This establishes durable memory DN2 as a distinct lineage from effector DN2. Whether dengue generates equivalent memory DN2 cells — and whether these contribute to the cross-reactive memory pool implicated in secondary dengue immunopathology — is unknown (see Sanz2025 - Human Atypical B Cells Overview, review).

  • Sanz2019 writes the EF pathway into the canonical classification — and simultaneously warns against how it does so. It sets out two pathways of B2 activation, the GC route to long-lived memory and plasma cells and “the extra-follicular pathway responsible for the generation of B cell blasts and short-lived plasmablasts”, while noting that the EF pathway can also generate long-term memory and long-lived PC in a T-cell-independent fashion. Table 1 then assigns DN2 the function “extrafollicular ASC precursors”. But the review’s own introduction argues against “attaching additional functional properties” to populations defined by surface phenotype — so that annotation is a hypothesis in table form (see Sanz2019 - Consistent Classification of Human B Cell Populations, review — no original data). This is the 2019 root of the constraint Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses later made explicit.

  • ★ A full in vitro reconstruction of the EF effector programme, with each signal assigned to a window. Human naive B cells can be driven to a T-bet^hi^IRF4^int^ IgD⁻CD27⁻ pre-ASC state that is phenotypically, transcriptionally and functionally equivalent to the DN2 cells expanded in SLE, using BCR + IFN-γ + IL-2 + IL-21 + BAFF + TLR7/8 ligand; >95% of naive cells convert. The signals are not interchangeable in time — IFN-γ acts in a discrete early priming window (days 0–3) and is obligate for pre-ASC formation, IL-21 acts late (days 3–6) and late IL-21 alone is as good as IL-21 throughout, and BCR signals must be transient: anti-Ig for days 0–3 only gave 49% ASCs, no anti-Ig 18%, and continuous anti-Ig just 2.8% (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human, n=20 HD + n=40 SLE + in vitro reconstruction). The continuous-BCR result is the counterintuitive one — sustained antigen receptor engagement suppresses EF ASC output, which bears on how a persistently antigen-rich acute infection like dengue would behave.

  • A myeloid, T-cell-independent route to dengue plasmablast output — filed here with an explicit sourcing caveat. DENV-2-infected CD14⁺ monocytes (>70% of which convert to a CD14⁺CD16⁺ phenotype by 48 h), cocultured 6 days with allogeneic resting CD19⁺ B cells plus IL-2 and CpG and no T cells, drove CD27⁺⁺CD38⁺⁺ plasmablasts to 22.8% of total B cells versus 3.83% with B cells alone (5.21% with monocyte-derived DCs). Anti-BAFF and TACI-Fc modestly reduced, and anti-IL-10 significantly blocked, differentiation, while anti-IL-6 and anti-IP-10 did not — the authors attribute the mechanism to BAFF/APRIL plus IL-10 (see Kwissa2014 - Monocytes Drive Plasmablast Differentiation in Dengue, in vitro, 4 independent experiments with 4 healthy blood donors). In the patient cohort, XBP-1 target-gene enrichment and rising plasmablast numbers both tracked late, low-viraemia illness (same source, n=28 acute secondary dengue). In the macaque model the same monocyte subset expanded 13-fold in absolute number in axillary lymph node by day 3 and acquired CD163/CD169, markers of subcapsular sinus macrophages — a site adjacent to migratory B cells (same source, NHP model, n=5).

    ⚠ Sourcing caveat. The paper never uses the words “extrafollicular” or “germinal centre” and makes no claim about response anatomy. Filing it under EF is the wiki’s judgement, on the narrow grounds that the demonstrated route is APC- and cytokine-driven, requires no T cell help, and yields plasmablast output from resting B cells — it is not the authors’ framing. The study also does not phenotype the IgD⁻CD27⁻ compartment, so it says nothing about DN2. Contrast Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, whose dengue help arm is Tph/IL-21-dependent: the myeloid and Tph arms have never been weighed against each other in the same patient.

Contradictions & Debates

  • ★ “GC-independent” ≠ “extrafollicular effector” — a distinction this wiki must hold. Glaros2025 - Multilayered Identity of B Cell Memory establishes GC-independent memory (eMBC) as a quiescent, low-SHM, largely unswitched cell that forms passively when antigen declines — explicitly “not an active differentiation process but rather a passive transition to quiescence.” The EF arm this page documents is a proliferative, ASC-generating effector programme with an active transcriptional identity (T-bet/ZEB2/IRF4/BLIMP-1-high, BACH2/FOXO1-absent). Both are GC-independent outputs of the same tripotent precursor, but they are different limbs. Two consequences: (a) fate-mapping results showing GC-independent memory dominance do not transfer to the EF effector arm without further argument; (b) conversely, the wiki’s EF evidence says nothing about eMBC abundance. Keep the claims separate.

  • ★ Physiological vs pathological routes to the same effector output disagree on what drives them. Glaros2025 (physiological immunization, mouse) reports that higher BCR affinity and stronger T cell help favour the early-PC limb, and that PC differentiation is readily induced by anti-IgM/anti-CD40 plus cytokines. Jenks2018 - DN2 B Cells and EF Pathway in SLE (SLE, human) reports DN2→PC proceeding on TLR7 + IL-21 + IFN-γ “signal 3” alone, without BCR stimulation, with CD40L actively inhibiting aNAV/DN2 generation. These are not contradictory observations so much as two different entry routes into an EF effector output — antigen-affinity-driven versus innate-signal-driven. Which one operates in acute dengue is untested and matters: the affinity-driven route predicts DENV-antigen-specific, affinity-selected plasmablasts; the innate route predicts a broader, less selected output. This is a sharper version of the open question already posed in the Jenks/Sutton bullet below.

  • Whether EF-derived memory B cells (i.e., DN cells) are genuinely GC-independent or represent cells that initiated but aborted GC entry is debated. Wei et al. acknowledge both models: (a) independent EF lineage; (b) failed/abortive GC entrants. Jenks2018 substantially resolves this for DN2 cells specifically: they are EF-derived effectors (CD40L inhibits their generation; TLR7 drives it). The original EF-origin debate now applies primarily to whether some DN1 cells might also arise extrafollicularly, or whether DN1 is entirely GC-derived.

  • The lower SHM rate of DN vs. CD27⁺ memory cells is consistent with EF origin but is not conclusive — it could also reflect selection against high-affinity autoreactive clones within GCs rather than GC exclusion.

  • Whether the TLR7-driven EF pathway operates identically in acute viral infections (where TLR7 ligands are physiological viral ssRNA rather than pharmacological R848) remains unestablished. The SLE context may amplify TLR7 signalling through genetically elevated IRF5/IRF7 haplotypes that are not present in all individuals.

  • Context-dependent pre-plasmablast identity — the Jenks2018 vs. Sutton2021 tension: Jenks2018 defines DN2 cells as pre-plasmablasts with high IRF4, BLIMP-1, and open PRDM1 chromatin in SLE. Sutton2021 finds that the same T-bet⁺/CD11c⁺/FCRL5⁺ population (alternative lineage atBCs) does NOT upregulate PC maintenance genes in healthy or infection contexts, with PCs detached from the pseudotime trajectory. The reconciliation — proposed by Sutton — is that PC differentiation capacity is context-dependent: chronic TLR7 stimulation in SLE can push atBCs toward PC fate, while acute infection or vaccination does not. This raises an unresolved question for dengue: does the inflammatory milieu of severe dengue (elevated type I IFN, IL-21, TLR7 ligand from viral ssRNA) create SLE-like conditions that activate the pre-plasmablast programme, or do dengue EF-phenotype B cells behave more like the Sutton malaria/vaccination model (alternative memory without PC differentiation)?

  • Memory B cells vs. naive B cells as EF precursors in dengue: In SLE, naive (acN) cells are the dominant EF ASC precursors (Tipton2015, n=5). In dengue, Ansari2025 (n=170 cohort, T-B coculture) shows Tph cells preferentially drive class-switched memory B cell→plasmablast differentiation, with naive B cells responding poorly. This likely reflects the endemic setting where most patients have pre-existing cross-reactive memory from prior DENV exposure. The precursor identity has implications for SHM distribution (memory-derived PBs carry prior GC-acquired mutations; naive-derived PBs would be germline-near) and for ADE potential (memory-derived cross-reactive clones vs. de novo polyreactive responses). Whether both precursor streams operate concurrently in dengue — and in what ratio — remains unresolved. Bhattacharya & Wong’s isotype-fate segregation model (citing Seifert et al. 2015) offers a mechanistic bridge: IgG⁺ memory B cells are predisposed to plasmablast/plasma cell differentiation, while IgM⁺ memory cells preferentially re-initiate GC reactions. If operative in dengue, this would explain why the massive PB wave is IgG-dominant and E-specific (IgG⁺ memory→PB) while IgM⁺ DENV-binding memory cells maintain memory identity or re-enter GCs (see Bhattacharya2016 - Memory B Cell Subset Selection in Secondary Dengue, commentary — no original data).

  • ★ Is “extrafollicular” a usable term for human blood studies at all? The consensus Perspective’s recommendation — reserve “EF” for responses whose extrafollicular location has been imaged — would remove the term from essentially every human study in this wiki, Woodruff2020 - EF B Cell Responses in COVID-19 included (whose companion tissue evidence in Kaneko2020 - GC Loss and TFH Block in COVID-19 establishes GC failure, which is an origin claim, not a location claim). Against this stands the field’s entrenched usage and the practical point the authors themselves concede: tissue imaging is “usually infeasible” for human work, and they offer no alternative method beyond stating criteria precisely. The wiki’s resolution: keep this page as the pathway page and the term where the literature uses it, but make claims in the GC-Independent Response vocabulary wherever the evidence is a blood panel (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • The authors did not reach internal consensus on two points, and both are recorded here rather than resolved. First, whether phase 2 — T-guided proliferation at the T-B border, with evidence of SHM and selection — should be called EF at all; the alternatives floated are “perifollicular”, “interfollicular”, “T-B border”, or “T-dependent non-GC”. Second, whether the T-B border belongs in the definition of an extrafollicular location. If it does, some responses currently called merely GC-independent are EF; if it does not, the classical sites (bridging channel, red pulp, medullary cords) are a narrower category than this wiki has historically implied (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

Double-Negative B Cell, Age-Associated B Cell, Atypical B Cell, DN2 B Cell, DN3 B Cell, Activated Naive B Cell, Germinal Center, Memory B Cell, Plasmablast, Somatic Hypermutation, Class Switch Recombination, T-bet, TLR7, TRAF5, IRF4, BLIMP-1, BACH2, ATF3, EGR, ZEB2, AID, Bcl-6, TNF-alpha, PD-1, Peripheral Helper T Cell, IL-21, CD40L, CXCR5, CXCR3, FCRL5, FRNT, Original Antigenic Sin, Antibody-Dependent Enhancement, CD11c, Immunohistochemistry, Early Memory B Cell, Tissue-Resident Memory B Cell, GC-Independent Response

Sources

Graph View

Backlinks